Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Atenolol
Drug ID BADD_D00178
Description Atenolol is a cardioselective beta-blocker used in a variety of cardiovascular conditions. Sir James Black, a Scottish pharmacologist, pioneered the use of beta-blockers for the management of angina pectoris in 1958 for which he received the Nobel Prize.[A178429] Beta-blockers quickly became popular in clinical use and where subsequently investigated for use in myocardial infarction, arrhythmias, and hypertension during the 1960s. Later they continued to be investigated for use in heart failure throughout the 1970-1980s. Atenolol itself was developed early on in this history by Alvogen Malta under the trade name Tenormin and received FDA approval in September, 1981.[label] Despite being one of the most widely prescribed beta blockers, evidence suggests atenolol may not significantly reduce mortality, and only modestly reduce the risk of cardiovascular disease in patients with hypertension.[A235850,A235855] A Cochrane review of patients being treated for primary hypertension shows that atenolol shows a risk ratio of 0.88 for cardiovascular disease risk and a risk ratio of 0.99 for mortality.[A235850,A235855] Similar results have been found in other meta-analyses.[A235860,A235865] A meta-analysis of over 145,000 patients showed the risk of stroke in patients taking atenolol may depend on the age of the patient.[A235865] The use of atenolol may need to be based on more patient factors than hypertension alone.[A235850,A235855,A235860,A235865]
Indications and Usage For the management of hypertention and long-term management of patients with angina pectoris
Marketing Status Prescription; Discontinued
ATC Code C07AB03
DrugBank ID DB00335
KEGG ID D00235
MeSH ID D001262
PubChem ID 2249
TTD Drug ID D01UXC
NDC Product Code 60760-787; 50090-2923; 67296-1589; 70934-142; 65862-169; 53002-2138; 68071-4274; 50090-5741; 50090-5363; 50090-3411; 68788-7784; 68788-7528; 52427-429; 0378-0231; 71335-1108; 51079-685; 48589-0007; 0904-7187; 0615-8026; 65841-024; 70518-0379; 65862-168; 65841-022; 70518-3036; 63187-710; 61919-914; 71335-0954; 55700-754; 68788-7535; 60429-027; 68071-4538; 53002-4108; 70934-537; 68382-022; 65862-170; 70518-0399; 71335-0988; 68788-7616; 67296-1270; 55700-755; 63187-092; 52427-430; 51079-684; 52427-431; 61919-854; 50090-5266; 60760-163; 67544-161; 70934-457; 64980-437; 60760-164; 43063-765; 68382-023; 71205-496; 67296-1288; 60687-605; 68071-4751; 68071-4526; 70518-0351; 70934-219; 67296-1726; 70518-2866; 60429-025; 65841-023; 29300-410; 60429-026; 71335-0912; 70518-2939; 0093-0787; 63629-2626; 0093-0753; 0615-8027; 68071-2248; 51604-0012; 67296-1201; 53002-1138; 0378-0757; 50090-0442; 71335-0540; 68071-1772; 60760-643; 70518-0882; 68071-4766; 70934-458; 68071-1771; 68382-024; 55154-5455; 12660-0007; 51079-759; 68071-4527; 42708-012; 0378-0218; 43353-986; 71335-0668; 61294-9994; 71335-1535; 43063-952; 63629-1785; 71205-229; 72189-135; 50090-3410; 72189-152; 68071-4553; 60760-437; 68788-7876; 63187-537; 67544-240; 57451-1115; 38779-0262; 64980-438; 68645-585; 0615-8373; 61919-664; 71335-1264; 50090-5738; 53002-1004; 51927-2467; 42185-7034; 29300-411; 67296-1732; 68071-5162; 50090-5233; 64980-439; 43063-805; 63187-201; 72189-146; 68071-5033; 67544-332; 70934-177; 0615-8372; 0093-0752; 71335-1616; 53002-2004; 29300-412; 61919-581; 63629-8029; 42708-143; 67296-1558; 60760-642; 60760-256; 43353-834; 50090-5408; 50090-3043; 61919-257; 65841-101; 70518-3007; 53002-1108; 70934-463; 49452-0020; 55154-5511; 72789-144; 71205-096; 61919-279; 50090-5367; 51927-0208
Synonyms Atenolol | Tenormine | Tenormin | ICI-66082 | ICI 66082 | ICI66082
Chemical Information
Molecular Formula C14H22N2O3
CAS Registry Number 29122-68-7
SMILES CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Coagulopathy01.01.02.0010.000074%Not Available
Cold sweat08.01.03.024; 23.02.03.0020.000185%Not Available
Colitis ischaemic07.08.01.004; 24.04.08.012--Not Available
Coma17.02.09.0010.000259%Not Available
Completed suicide08.04.01.010; 19.12.01.0010.000578%Not Available
Confusional state17.02.03.005; 19.13.01.0010.000665%
Constipation07.02.02.001--
Coronary artery disease02.02.01.001; 24.04.04.006--Not Available
Cough22.02.03.001--
Creatinine renal clearance decreased13.13.01.0130.000074%Not Available
Crohn's disease07.08.01.015; 10.02.01.0050.000148%Not Available
Crying08.01.03.005; 12.02.11.001; 17.02.05.013; 19.04.02.0020.000074%Not Available
Cutaneous vasculitis10.02.02.003; 23.06.02.001; 24.05.02.004--Not Available
Cyanosis02.01.02.002; 22.02.02.007; 24.03.01.0070.000222%
Death08.04.01.001--
Dehydration14.05.05.0010.000333%
Delirium19.13.02.001--
Depressed level of consciousness17.02.04.0020.000296%
Depressed mood19.15.02.0010.000148%Not Available
Depression19.15.01.0010.000665%
Dermatitis23.03.04.0020.000074%Not Available
Dermatitis exfoliative10.01.01.004; 23.03.07.001--
Diarrhoea07.02.01.001--
Discomfort08.01.08.0030.000111%Not Available
Disorientation17.02.05.015; 19.13.01.002--Not Available
Disturbance in attention17.03.03.001; 19.21.02.002--
Dizziness02.01.02.004; 17.02.05.003; 24.06.02.0070.002033%
Dizziness postural02.01.02.005; 17.02.05.004; 24.06.02.0080.000370%Not Available
Drug abuse19.07.02.0100.000154%Not Available
Drug hypersensitivity10.01.01.001--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 17 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene